Tumor-targeting multifunctional micelles for imaging and chemotherapy of advanced bladder cancer

Nanomedicine

Volumn 8, Issue 8, 2013, Pages 1239-1251

  Lin, Tzu Yin ^a   Li, Yuan Pei ^a   Zhang, Hongyong ^a   Luo, Juntao ^b   Goodwin, Neal ^c   Gao, Tingjuan ^d   White, Ralph De Vere ^e   Lam, Kit S ^a   Pan, Chong Xian ^a,e,f  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^c JACKSON LABORATORY   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f Northern California Veteran's Healthcare System   (United States)

Author keywords

bladder cancer specific ligand; bladder urothelial carcinoma; diagnostic imaging; nanoparticle; targeted therapy

Indexed keywords

CASPASE 3; CASPASE 7; CREMOPHOR; PACLITAXEL;

ADVANCED CANCER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CANCER; BONE MARROW TOXICITY; CANCER CELL; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER INHIBITION; CELL CYCLE ARREST; CLICK CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG RELEASE; ENZYME ACTIVITY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMAGING; IN VITRO STUDY; IN VIVO STUDY; MAST CELL DEGRANULATION; MAXIMUM TOLERATED DOSE; MICELLE; MICROTUBULE; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; SURFACE PROPERTY; TREATMENT OUTCOME; TUMOR XENOGRAFT;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG DELIVERY SYSTEMS; HUMANS; MAXIMUM TOLERATED DOSE; MICE; MICELLES; PACLITAXEL; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 84893161267     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.12.150     Document Type: Article

References (30)

1. Kirkali Z, Chan T, Manoharan M et al. Bladder cancer: Epidemiology, staging and grading, and diagnosis. Urology 66, 4-34 (2005
2. Herr HW, Dotan Z, Donat SM, Bajorin DF. Defining optimal therapy for muscle invasive bladder cancer. J. Urol. 177, 437-443 (2007
3. Matsumoto K, Kikuchi E, Horinaga M et al. Intravesical interleukin-15 gene therapy in an orthotopic bladder cancer model. Hum. Gene Ther. 22, 1423-1432 (2011
4. Seth S, Matsui Y, Fosnaugh K et al. RNAi-based therapeutics targeting survivin and PLK1 for treatment of bladder cancer. Mol. Ther. 19, 928-935 (2011
5. Chihara Y, Fujimoto K, Kondo H et al. Anti-Tumor effects of liposome-encapsulated titanium dioxide in nude mice. Pathobiology 74, 353-358 (2007
6. Cho EJ, Yang J, Mohamedali KA et al. Sensitive angiogenesis imaging of orthotopic bladder tumors in mice using a selective magnetic resonance imaging contrast agent containing VEGF121/rGel. Invest. Radiol. 46, 441-449 (2011
7. Lu Z, Yeh TK, Tsai M, Au JL, Wientjes MG. Paclitaxel-loaded gelatin nanoparticles for intravesical bladder cancer therapy. Clin. Cancer Res. 10, 7677-7684 (2004
8. Winquist E, Ernst DS, Jonker D et al. Phase II trial of pegylated-liposomal doxorubicin in the treatment of locally advanced unresectable or metastatic transitional cell carcinoma of the urothelial tract. Eur. J. Cancer 39, 1866-1871 (2003
9. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 46, 6387-6392 (1986
10. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: The key role of tumor-selective macromolecular drug targeting. Adv. Enzyme Regul. 41, 189-207 (2001
11. Wu AM, Yazaki PJ, Tsai S et al. High-resolution microPET imaging of carcinoembryonic antigen-positive xenografts by using a copper-64-labeled engineered antibody fragment. Proc. Natl Acad. Sci. USA 97, 8495-8500 (2000
12. Yang L, Peng XH, Wang YA et al. Receptor-Targeted nanoparticles for in vivo imaging of breast cancer. Clin. Cancer Res. 15, 4722-4732 (2009
13. Hussain S, Pluckthun A, Allen TM, Zangemeister-Wittke U. Antitumor activity of an epithelial cell adhesion molecule targeted nanovesicular drug delivery system. Mol. Cancer Ther. 6, 3019-3027 (2007
14. Kirpotin DB, Drummond DC, Shao Y et al. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res. 66, 6732-6740 (2006
15. Pun SH, Tack F, Bellocq NC et al. Targeted delivery of RNA-cleaving DNA enzyme (DNAzyme) to tumor tissue by transferrin-modified, cyclodextrin-based particles. Cancer Biol. Ther. 3, 641-650 (2004
16. Zhang H, Aina OH, Lam KS et al. Identification of a bladder cancer-specific ligand using a combinatorial chemistry approach. Urol. Oncol. 30(5), 635-645 (2012
17. Lin TY, Zhang H, Wang S et al. Targeting canine bladder transitional cell carcinoma with a human bladder cancer-specific ligand. Mol. Cancer 10(1), 9 (2011
18. Luo J, Xiao K, Li Y et al. Well-defined, size tunable, multifunctional micelles for efficient paclitaxel delivery for cancer treatment. Bioconjug. Chem. 21, 1216-1224 (2010
19. Lin T-y, Zhang H, Luo J et al. Multifunctional targeting micelle nanocarriers with both imaging and therapeutic potential for bladder cancer. Int. J. Nanomed. 7, 2793-2804 (2012
20. Gelderblom H, Verweij J, Nooter K, Sparreboom A. Cremophor EL. The drawbacks and advantages of vehicle selection for drug formulation. Eur. J. Cancer 37, 1590-1598 (2001
21. Xiao K, Luo J, Fowler WL et al. A self-Assembling nanoparticle for paclitaxel delivery in ovarian cancer. Biomaterials 30, 6006-6016 (2009
22. Tornoe CW, Christensen C, Meldal M Peptidotriazoles on solid phase: [1,2,3]-Triazoles by regiospecific copper(i)-catalyzed 1,3-dipolar cycloadditions of terminal alkynes to azides. J. Org. Chem. 67, 3057-3064 (2002
23. Shultz LD, Lyons BL, Burzenski LM et al. Human lymphoid and myeloid cell development in NOD/LtSz-SCID IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. J. Immunol. 174, 6477-6489 (2005
24. Kato J, Li Y, Xiao K et al. Disulfide cross linked micelles for the targeted delivery of vincristine to B-cell lymphoma. Mol. Pharm. 4(9), 1727-1735 (2012
25. Xiao K, Li Y, Lee JS et al. 'OA02' peptide facilitates the precise targeting of paclitaxel loaded micellar nanoparticles to ovarian cancer in vivo. Cancer Res. 72, 2100-2110 (2012
26. Li Y, Xiao W, Xiao K et al. Well-defined, reversible boronate crosslinked nanocarriers for targeted drug delivery in response to acidic pH values and cis-diols. Angew. Chem. Int. Ed. Engl. 51(12), 2864-2869 (2012
27. Grenader T, Goldberg A, Gabizon A Monitoring long-Term treatment with pegylated liposomal doxorubicin: How important is intensive cardiac follow-up? Anticancer Drugs 21, 868-871 (2010
28. Theodoulou M, Hudis C Cardiac profiles of liposomal anthracyclines: Greater cardiac safety versus conventional doxorubicin? Cancer 100, 2052-2063 (2004
29. Kesterson JP, Odunsi K, Lele S. High cumulative doses of pegylated liposomal doxorubicin are not associated with cardiac toxicity in patients with gynecologic malignancies. Chemotherapy 56, 108-111 (2010
30. Sparreboom A, van Tellingen O, Nooijen WJ, Beijnen JH Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL. Cancer Res. 56, 2112-2115 (1996